Versatope Biotechnology Platform


Our clinical stage company uses designer extracellular nano-vesicles to provide cross-strain immunity to infectious diseases, including Influenza, malaria and targeted therapeutics for cancer.


We have a versatile platform based on molecular engineering of proprietary cell lines that produce Recombinant Extracellular Transport Vesicles (RET-V's).



The Power of Versatope's Vesicles

  • Display Multiple Viral Variants on a Single Vesicle 
  • Design More Effective Vaccines
  • Deliver therapeutic RNA directly into cancer cells 
  • Protect Against Emerging Strains
  • Confer Long-Term Immunity
  • Rapid Synthesis, Scale up and Distribution
  • Thermostable

A 3-D View of Versatope's Vaccine Design

Take a voyage inside Versatope's vaccine vesicles and learn how we design multi-strain vaccines using probiotic vesicles and why this gives us a competitive advantage over single strain vaccines. 

Hear our team describe Versatope's state of the art manufacturing and analytical equipment that enables us to deliver immunity.